Quarterly report pursuant to Section 13 or 15(d)

Licenses and Collaborations (Details Narrative)

v2.4.0.8
Licenses and Collaborations (Details Narrative) (USD $)
Sep. 30, 2014
Dec. 31, 2013
Dec. 31, 2011
Licenses And Collaborations Details Narrative      
Additional exercisable options   $ 37,500,000  
Common stock purchased by Teva   687,442  
Value of stock purchased by Teva   7,500,000  
Liability, initial fair value of Teva options     4,200,000
Common stock issued 123,000    3,100,000
Transaction costs     $ 172,000,000